Skip to content

Healthcare stock up 50% in 2024, and it might be just the beginning

Investor alert: The next healthcare stock set to revolutionize the industry
Elmaz Sabovic

The shares of Hims & Hers Health (NYSE: HIMS), a direct-to-consumer telehealth company, have surged by more than 40% since the release of its Q4 earnings report and more than 50% since the start of the year.

HIMS YTD stock price chart. Source: Google Finance
HIMS YTD stock price chart. Source: Google Finance

Despite being relatively unknown with a $2 billion valuation, the company has caught the interest of investors due to its impressive growth and improving financial performance.

It might feel like a missed opportunity when news emerges of a stock already gaining momentum. However, there’s always potential for new opportunities, as HIMS still offers a reasonable valuation and entry point.

Strong performance since the IPO

Since its IPO in 2021, Hims & Hers has consistently demonstrated robust growth. Over the past three years, the company has nearly tripled its subscriber base to over 1.5 million, accompanied by impressive revenue growth. While Hims & Hers needs to maintain its execution, substantial evidence suggests that HIMS is on the right track, which could drive significant long-term expansion.

Considering healthcare’s broad appeal, every adult represents a potential customer, and Hims & Hers’ current 1.5 million patient base is just a fraction of the US population alone. Management estimates that each specialty focus represents a market of between 80 million to 100 million US adults.

Expanding customer base of Hims & Hers. Source: Hims & Hers
Expanding customer base of Hims & Hers. Source: Hims & Hers

There is still room for growth of HIMS

Despite its recent surge, the stock trades at about 35 times its projected 2024 earnings. With management expecting a 38% revenue increase this year and the company’s strong performance in 2023 surpassing initial forecasts, there’s a possibility of conservative estimates.

Additionally, next year’s earnings per share estimate of $0.50, reflecting a 31% increase, may undervalue Hims & Hers’ operational efficiency. 

Hims & Hers 2024 outlook. Source: Hims & Hers
Hims & Hers 2024 outlook. Source: Hims & Hers

Given the current earnings growth rate and P/E ratio, the stock appears undervalued, with the potential for further outperformance, potentially offering a great option for long-term investment.

Buy stocks now with eToro – trusted and advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts